Bladder Cancer Clinical Trial
Official title:
Evaluation of the Survivin Urine mRNA Assay to Estimate Risk of Bladder Cancer Found on Cystoscopy
The purpose of this clinical trial is to evaluate the ability of urinary Survivin mRNA measurement to estimate the risk of bladder cancer at the time of cystoscopy in subjects with no prior history of bladder cancer presenting with microscopic or macroscopic hematuria.
Bladder cancer is the fourth most common cancer in men and ninth most common cancer in
women, accounting for more than 60,000 new cases and ~12,000 deaths in North America in
2004. Cystoscopy and urinary cytology is the standard of care for detection of bladder
cancer, but cystoscopy is expensive and invasive, while cytology has low sensitivity. New,
noninvasive, diagnostic tools for bladder cancer detection have been developed, but their
application in clinical practice has been limited due to low sensitivity and specificity of
the assays. Survivin, an anti-apoptotic protein, is capable of regulating both cell
proliferation and apoptotic cell death, and is over-expressed in most human cancers but not
in normal adult tissues. The purpose of this clinical trial is to evaluate the ability of
urinary Survivin mRNA measurement to estimate the risk of bladder cancer at the time of
cystoscopy in subjects with no prior history of bladder cancer presenting with microscopic
or macroscopic hematuria.
This study is designed to be a prospective, multicenter, double blind, clinical study in
subjects >50 years old with no prior history of bladder cancer and confirmed hematuria
(microscopic and/or macroscopic) presenting to a urologist.
The primary objective of the study is to estimate the risk of bladder cancer at the time of
cystoscopy in subjects >50 years old with no prior history of bladder cancer and confirmed
hematuria using urinary Survivin mRNA levels.
The secondary objective of the study is for comparison of a multivariate predictive
algorithm using urinary Survivin mRNA levels and subject risk factors, such as age, sex,
race, and smoking history, for estimation of the risk of bladder cancer at the time of
cystoscopy in subjects >50 years old with no prior history of bladder cancer and confirmed
hematuria to the use of urinary Survivin mRNA levels alone.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |